Shenzhen - Delayed Quote CNY

Yantai Zhenghai Biotechnology Co., Ltd. (300653.SZ)

23.85 +0.53 (+2.27%)
At close: April 26 at 3:04 PM GMT+8
Key Events
Loading Chart for 300653.SZ
DELL
  • Previous Close 23.32
  • Open 22.30
  • Bid 23.81 x --
  • Ask 23.85 x --
  • Day's Range 23.25 - 23.87
  • 52 Week Range 18.11 - 48.13
  • Volume 2,375,499
  • Avg. Volume 2,447,513
  • Market Cap (intraday) 4.293B
  • Beta (5Y Monthly) 0.05
  • PE Ratio (TTM) 22.50
  • EPS (TTM) 1.06
  • Earnings Date --
  • Forward Dividend & Yield 0.60 (2.52%)
  • Ex-Dividend Date May 30, 2023
  • 1y Target Est 31.34

Yantai Zhenghai Biotechnology Co., Ltd. engages in the research and development, production, and marketing of regenerative medical materials in China. The company offers oral cavity repair membrane, absorbable dural (spinal) patch biological membrane patch, and bone repair material products under the Heal-All brand. It also provides skin repair film and self-etching adhesive products under the Heal-Full brand name, as well as surgical caulking sponge products under the Heal Bleed brand. The company was founded in 2003 and is based in Yantai, China.

www.zhbio.com

332

Full Time Employees

December 31

Fiscal Year Ends

Related News

Performance Overview: 300653.SZ

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

300653.SZ
17.82%
SSE Composite Index
3.82%

1-Year Return

300653.SZ
45.74%
SSE Composite Index
5.40%

3-Year Return

300653.SZ
25.53%
SSE Composite Index
11.10%

5-Year Return

300653.SZ
7.63%
SSE Composite Index
1.13%

Compare To: 300653.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 300653.SZ

Valuation Measures

Annual
As of 4/26/2024
  • Market Cap

    4.29B

  • Enterprise Value

    3.62B

  • Trailing P/E

    22.50

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    10.39

  • Price/Book (mrq)

    4.53

  • Enterprise Value/Revenue

    8.75

  • Enterprise Value/EBITDA

    15.14

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    46.16%

  • Return on Assets (ttm)

    11.68%

  • Return on Equity (ttm)

    21.06%

  • Revenue (ttm)

    413.65M

  • Net Income Avi to Common (ttm)

    190.96M

  • Diluted EPS (ttm)

    1.06

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    675.19M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    90.49M

Research Analysis: 300653.SZ

Analyst Price Targets

28.00
31.34 Average
23.85 Current
34.67 High
 

Fair Value

 

Company Insights: 300653.SZ

People Also Watch